<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789905</url>
  </required_header>
  <id_info>
    <org_study_id>B1811187</org_study_id>
    <nct_id>NCT01789905</nct_id>
  </id_info>
  <brief_title>Tygacil Drug Use Investigation</brief_title>
  <acronym>TIGER</acronym>
  <official_title>Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-Drug Resistance.)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect retrospectively the effectiveness and safety information of tigecycline related
      to their appropriate use in daily practice.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The clinical response was assigned by the investigator. A clinical response of cure was defined as: Test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. Test-of-cure performed 10-28 days after last dose of study drug.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intra-Abdominal Infections</condition>
  <condition>Skin Disease, Infectious</condition>
  <arm_group>
    <arm_group_label>Tigecycline (Tygacil)</arm_group_label>
    <description>Subjects who are treated with tigecycline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline (Tygacil)</intervention_name>
    <description>Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.</description>
    <arm_group_label>Tigecycline (Tygacil)</arm_group_label>
    <other_name>Tygacil, Tigecycline</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients whom an investigator involving B1811187 prescribes the tigecycline (Tygacil).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who are prescribed tigecycline (Tygacil).

        Exclusion Criteria:

          -  Subject who have been prescribed tigecycline (Tygacil).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1811187&amp;StudyName=Tygacil%20Drug%20Use%20Investigation</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tygacil</keyword>
  <keyword>Tigecycline</keyword>
  <keyword>Post marketing surveillance</keyword>
  <keyword>Japanese</keyword>
  <keyword>Infection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
